Developments in RET-targeted therapies have led to a paradigm shift in the management of advanced thyroid cancer. However, resistance to these drugs has been observed to develop through a variety of mechanisms, so precise monitoring is required to detect and react to disease development.
This episode offers insight into relevant mechanisms of resistance to RET inhibitors in thyroid cancer. It also considers how strategies such as combinations of targeted therapies and liquid biopsy could potentially help tackle the development of resistance. To answer questions on this topic, we have invited Professor Bruce Robinson to join us. He is a Professor of Medicine and Endocrinologist at the University of Sydney, Australia.
Funding Information:
This episode is supported by an educational grant from Eli Lilly, who have had no influence on the content or choice of faculty.
References

Román-Gil MS, Pozas J, Rosero-Rodríguez D, et al. Resistance to RET targeted therapy in Thyroid Cancer: Molecular basis and overcoming strategies. Cancer Treat Rev. 2022;105:102372. doi: 10.1016/j.ctrv.2022.102372
Subbiah V, Cascone T, Hess KR et al. Multi-kinase RET inhibitor vandetanib combined with mTOR inhibitor everolimus in patients with RET rearranged non-small cell lung cancer. Journal of Clinical Oncology. 36 (15). Doi: 10.1200/JCO.2018.36.15_suppl.9035